Welcome to our dedicated page for Ernexa Therapeutics SEC filings (Ticker: ERNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ernexa Therapeutics filings document a Delaware biotechnology issuer developing synthetic allogeneic iMSC cell therapies and reporting as a public company with common stock and common stock purchase warrants listed on Nasdaq. Registration statements and amendments disclose the company's cellular-therapy business, operating and financial results, capital structure, risk factors, clinical and regulatory development disclosures, and offering-related security terms.
Current reports on Form 8-K cover material events including amendments to the certificate of incorporation for a 1-for-25 reverse stock split, Nasdaq minimum-bid compliance notices, Regulation FD investor-presentation materials, changes in the independent registered public accounting firm, going-concern explanatory disclosures and internal-control matters.
Ernexa Therapeutics Inc. (ERNA) has a new initial insider ownership report. Director Robert J. Spiegel filed a Form 3 as a reporting person of the company. The filing lists no reportable transactions, derivative positions, or equity holdings for him as of the reporting date.
Ernexa Therapeutics Inc. (ERNA) reported that on September 16, 2026 it made a corporate fact sheet and an investor presentation available to investors, furnished as Exhibits 99.1 and 99.2 to this report under a Regulation FD disclosure.
The company states that these materials, including their “Forward-Looking Statements” disclosure, are incorporated by reference into this Item 7.01 and will also be accessible on its investor relations website starting September 17, 2026. Ernexa explains that it uses its website as a regular channel to distribute important and time‑critical company information, while clarifying that the furnished materials are not deemed filed for purposes of Section 18 of the Exchange Act.
Ernexa Therapeutics Inc. (ERNA) reports that its board of directors has appointed Robert J. Spiegel, M.D. as a director, effective September 14, 2026. He will serve until a successor is duly elected and qualified or until earlier death, resignation, or removal.
Dr. Spiegel will be compensated under Ernexa’s Board of Directors Compensation Plan that became effective August 15, 2026 and is described in the company’s Form 10-Q for the quarter ended June 30, 2026. The company states there are no appointment-related arrangements, no family relationships with current leadership, and no related-party transactions with Dr. Spiegel that are reportable under Item 404(a) of Regulation S-K.
Ernexa Therapeutics Inc. (ERNA) reported that director James Arthur Bristol received two grants of stock options to purchase common stock. On 2026-08-31, he was granted 8,320 options with a $4.57 exercise price, expiring on 2036-08-31, vesting one-third on the first anniversary and the remainder in 24 monthly installments, subject to continued service. He was also granted 5,083 options at a $4.57 exercise price, expiring on 2036-08-31, in lieu of prorated 2026 director cash compensation under the Director's Compensation Plan, with 100% vesting on December 31, 2026, subject to continued service.
Ernexa Therapeutics Inc. (ERNA) reported that director Peter Cicala received two grants of stock options on August 31, 2026. One grant covers 5,943 options with an exercise price of $4.57 per share, vesting one-third on the first anniversary and the rest in 24 monthly installments, expiring August 31, 2036. A second grant covers 5,083 options at $4.57 per share, issued in lieu of prorated 2026 director cash compensation under the Director's Compensation Plan, vesting 100% on December 31, 2026, also expiring August 31, 2036.
Ernexa Therapeutics Inc. (ERNA) reported that director David Polinsky received a grant of stock options covering 5,083 shares of common stock. The options have an exercise price of $4.57 per share, were granted in lieu of prorated director cash compensation for 2026 under the company’s 2026 Omnibus Equity Incentive Plan, and expire on August 31, 2036. Subject to continued service, 100% of the options vest on December 31, 2026, and Polinsky’s total holdings of this option grant are 5,083 options following the reported transaction.
Ernexa Therapeutics Inc. (ERNA) reported that director William A. Wexler received a grant of stock options for 5,943 shares of common stock. The options have an exercise price of $4.57 per share and expire on August 31, 2036. Following this grant, Wexler holds 5,943 stock options directly. Vesting is time-based: one-third of the underlying shares vest on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter, subject to continued service.
Ernexa Therapeutics Inc. (ERNA) reported that director Elena Ratner received a grant of stock options covering 5,944 shares of common stock at an exercise price of $4.57 per share. Subject to continued service, one-third of the option vests on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments through August 31, 2036.
Ernexa Therapeutics Inc. (ERNA) reported that President and CEO Luther Sanjeev received a grant of stock options. The award covers 118,848 options to acquire Ernexa common shares at an exercise price of $4.57 per share, expiring on 2036-08-31. Following this grant, Sanjeev holds 118,848 derivative securities of this type.
The options vest over time: one-third of the underlying shares vest on the first anniversary of the grant date, with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter, subject to continued service.
Ernexa Therapeutics Inc. (ERNA) reported the initial equity holdings of director David Polinsky. He indirectly holds a warrant, through Polo3K, LLC, to purchase 8,000 shares of Common Stock at an exercise price of $17.00 per share, and indirectly holds 8,000 shares of Common Stock.
The warrant is scheduled to expire on February 10, 2031, but will instead expire earlier if triggered by clinical milestones: specifically, on the 180th calendar day following public release of clinical trial data from the first cohort of the Phase 1 study of ERNA-101.